NCT03915886View on ClinicalTrials.gov

A Study of JNJ-64530440 in Healthy Japanese Male Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

July 17, 2019

Study Completion Date

July 17, 2019

Conditions
Healthy
Interventions
DRUG

JNJ-0440

JNJ-0440 tablets will be administered orally.

DRUG

Placebo

Matching placebo tablets will be administered orally.

Trial Locations (1)

130-0004

Sumida Hospital, Tokyo

Sponsors
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Janssen Pharmaceutical K.K.

INDUSTRY